MDR in FY22

Items and milestones that MedAdvisor should be achieving in H1FY22 (in no particular order):

1. Cotiviti (nee HMS) to nominate a Board Member
2. 2M subscribers
3. 400 UK pharmacies onboarded
4. 30% of Adheris pharmacy network doing digital programs
   • Currently 7 programs live which represents 6% or 1500 pharmacies
5. Convert more AU pharmacies to take up the premium pricing tier

The FY21 report, coming later this month, will show the Top20.

We know PVM and Jencay have been big buyers since December last year.

Any on-market buys before April was above today's share price.

The API deal didn't get a $ symbol.

I hope Management hasn't forgotten how to submit ASX announcement's as price sensitive.

If they can throw in a few of these (that are not 4C, 4D, 4E reports) in the coming months and re-rate their CY2021 revenue target of $55-$57M, then a FY22 target of $65-$70M should hopefully get the share price moving.

Management have stated the December quarter is their best, typically earning 28%. Show us ~$18M in December, then in 2022 they can legitimately say they've planted their flag in the US and the UK.